Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: An observational study

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2459-2462

  Markou, Nikolaos ^a   Fousteri, Marizoza ^b   Markantonis, Sophia L ^b   Zidianakis, Basilios ^b   Hroni, Despina ^c   Boutzouka, Eleni ^b   Baltopoulos, George ^b  

^a THRIASIO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

Colistin concentrations; Critical care; Extracorporeal clearance; Renal replacement therapy

Indexed keywords

COLISTIMETHATE; MEROPENEM;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; BLOODSTREAM INFECTION; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; EFFLUENT; GRAM NEGATIVE SEPSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; OBSERVATIONAL STUDY; SEPTIC SHOCK; STEADY STATE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; CRITICAL ILLNESS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEPSIS; SERUM; TIME FACTORS;

EID: 84866601223     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks257     Document Type: Article

References (11)

1. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-5.
2. Karvanen M, Plachouras D, Friberg LE et al. Pharmacokinetics of colistin after intravenous administration in critically ill patients receiving continuous venovenous haemodiafiltration. In: Abstracts of the Nineteenth European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 2009. Abstract P1660, S473. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
3. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94
4. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
5. Markantonis SL, Markou N, Fousteri M et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009; 53: 4907-10.
6. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007; 13: 645-51.
7. Ricci Z, Ronco C, Bachetoni A et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10: R67.
8. Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362-79.
9. Dudhani RV, Turnidge JD, Coulthard K et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54: 1117-24.
10. Dudhani RV, Turnidge JD, Nation RL et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 5: 1984-90.
11. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.